Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

1.

Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance.

Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Sep 11:1-9. doi: 10.1080/21678421.2017.1363242. [Epub ahead of print]

PMID:
28891333
2.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group.

Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28.

3.

An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction.

Shefner JM, Sabbagh MN.

Neurotherapeutics. 2017 Jan;14(1):1-3. doi: 10.1007/s13311-016-0502-y. No abstract available.

PMID:
27933486
4.

Strength Testing in Motor Neuron Diseases.

Shefner JM.

Neurotherapeutics. 2017 Jan;14(1):154-160. doi: 10.1007/s13311-016-0472-0. Review.

PMID:
27600518
5.

Quantitative strength testing in ALS clinical trials.

Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M.

Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6.

6.

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.

Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA; ; ON BEHALF OF THE BENEFIT-ALS STUDY GROUP.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-35. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16.

PMID:
26982815
7.

A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group.

Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24.

8.

Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone.

Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME.

Toxicol Rep. 2015;2:1396-1403.

9.

Reply.

Rutkove SB, Shefner JM, Bowser R, Benatar M.

Ann Neurol. 2016 Feb;79(2):334. doi: 10.1002/ana.24586. Epub 2016 Jan 19. No abstract available.

PMID:
26705262
10.

To travel or not to travel: The modern day struggle of the academic researcher.

Rutkove SB, Shefner JM, Bowser R, Benatar M.

Ann Neurol. 2015 Nov;78(5):667-9. doi: 10.1002/ana.24516. Epub 2015 Sep 18. No abstract available.

PMID:
26343928
11.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

12.

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM; Ceftriaxone Study Investigators.

Lancet Neurol. 2014 Nov;13(11):1083-1091. doi: 10.1016/S1474-4422(14)70222-4. Epub 2014 Oct 5.

13.

Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?

Shefner JM, Mihaila D.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):337-43. doi: 10.3109/21678421.2014.918150. Epub 2014 Jun 11. Review.

PMID:
24918689
14.

Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Harmatz JS, Schoenfeld D, Greenblatt DJ.

J Clin Pharmacol. 2014 Oct;54(10):1180-7. doi: 10.1002/jcph.317. Epub 2014 May 16. Erratum in: J Clin Pharmacol. 2014 Nov;54(11):1320.

15.

Predicting success: optimizing phase II ALS trials for the transition to phase III.

Berry JD, Cudkowicz ME, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):1-8. doi: 10.3109/21678421.2013.838969. Review.

PMID:
24588460
16.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

17.

Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.

18.

Designing clinical trials for dystonia.

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA.

Neurotherapeutics. 2014 Jan;11(1):117-27. doi: 10.1007/s13311-013-0221-6. Review.

19.

Electrical impedance myography correlates with standard measures of ALS severity.

Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Benatar M, Sharma KR, Narayanaswami P, Raynor EM, Watson ML, Shefner JM.

Muscle Nerve. 2014 Mar;49(3):441-3. doi: 10.1002/mus.24128. Epub 2013 Dec 19.

PMID:
24273034
20.

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators.

Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].

PMID:
24067398

Supplemental Content

Loading ...
Support Center